Novartis: raises medium-term sales forecast
(CercleFinance.com) - Ahead of its Investor Day, Novartis has raised its medium-term guidance, now targeting average annual sales growth of 6% over 2023-2028 (instead of 5%), with 5% between 2024 and 2029.
The Swiss healthcare giant also says it remains on track to deliver a core operating margin of 40% or more by 2027, benefiting from continued strong sales growth and productivity improvements.
Novartis further boasts a pipeline of at least 30 high-value medicines in development that should support continued sales growth in the mid-single digits beyond 2029.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The Swiss healthcare giant also says it remains on track to deliver a core operating margin of 40% or more by 2027, benefiting from continued strong sales growth and productivity improvements.
Novartis further boasts a pipeline of at least 30 high-value medicines in development that should support continued sales growth in the mid-single digits beyond 2029.
Copyright (c) 2024 CercleFinance.com. All rights reserved.